Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 5/20 | 0.79 |
| ▸ | AURKA | O14965 | 1/20 | 0.79 |
| ▸ | PLK1 | P53350 | 1/20 | 0.79 |
| ▸ | IGF1R | P08069 | 15/20 | 0.71 |
| ▸ | PIM1 | P11309 | 1/20 | 0.70 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.70 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.68 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.68 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.68 |
| ▸ | MELK | Q14680 | 1/20 | 0.68 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.68 |
| ▸ | NEK6 | Q9HC98 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12499331 | 0.95 | TTK (0.79) | TTKAURKAPLK1IGF1RPIM1 | |
| SCHEMBL1895201 | 0.92 | TTK (0.80) | TTKAURKAPLK1IGF1RPIM1 | |
| SCHEMBL1895138 | 0.91 | TTK (0.78) | TTKAURKAPLK1IGF1RPIM1 | |
| SCHEMBL1559206 | 0.88 | TTK (1.00) | TTKAURKAPLK1PIM1PIM2 | |
| SCHEMBL12698406 | 0.86 | TTK (0.79) | TTKAURKAPLK1IGF1RPIM1 | |
| SCHEMBL12698458 | 0.84 | TTK (1.00) | TTKAURKAPLK1IGF1RPIM1 | |
| SCHEMBL1895216 | 0.84 | TTK (0.83) | TTKAURKAPLK1IGF1RPIM1 | |
| SCHEMBL1560088 | 0.83 | TTK (0.79) | TTKAURKAPLK1IGF1RPIM1 | |
| SCHEMBL10191955 | 0.83 | IGF1R (1.00) | IGF1R | |
| SCHEMBL12698376 | 0.83 | TTK (1.00) | TTKAURKAPLK1IGF1RPIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2303891-B1 | PYRAZOLO-QUINAZOLINES AS PROTEIN KINASE ACTIVITY MODULATORS | SERVIER LAB (FR) | 2016-02-17 | — | — | EP | disclosed |
| US-8846701-B2 | Pyrazolo-quinazolines | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-09-30 | — | — | US | disclosed |
| US-20110105542-A1 | PYRAZOLO--QUINAZOLINES | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105542-A1 | PYRAZOLO--QUINAZOLINES | PDXK, MAP4K5, MAP3K1 | TTK 8/4885AURKA 370/4885PLK1 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.